Patients treated for multiple myeloma at facilities that see a higher number of multiple myeloma patients annually had better outcomes compared to patients who were treated at…
Longer duration of maintenance therapy with Revlimid (lenalidomide) after autologous hematopoietic stem cell transplantation (HSCT) prolongs survival for multiple myeloma patients without increasing…
Inhibiting a key protein in the tumor microenvironment using Noxxon’s experimental agent NOX-A12 may enhance the clinical activity of immunotherapies that boost T-cells or natural…
Amgen announced that its RANKL inhibitor, Xgeva (denosumab) met its primary endpoint in a  Phase 3 trial as a potential treatment for bone complications in…
A three-drug therapy combination consisting of Darzalex (daratumumab) with Revlimid (lenalidomide) and Decadron (dexamethasone) shows real potential in increasing survival in patients with…
Understanding how multiple myeloma develops and responds to therapies may be easier using a new mouse model developed at Yale University School of Medicine. The model supports…
High-risk multiple myeloma patients may benefit markedly from galinpepimut-S, an experimental immunotherapy from SELLAS Life Sciences, following autologous stem cell transplant (ASCT), according to recent…
Robots can do all sorts of tasks to improve cancer treatment and now researchers have added room cleaning to the list. Indeed, Robots that use…
The U.S. Food and Drug Administration (FDA) is giving priority review to a supplemental Biologics License Application (sBLA) to approve Genmab‘s Darzalex (…
The communication between multiple myeloma cells and healthy bone marrow cells is an important step in disease progression, researchers have found, showing that multiple myeloma…